Skip to main content

Table 3 Needs by clinicopathological characteristics of study subjects

From: Unmet needs and related factors of Korean breast cancer survivors: a multicenter, cross-sectional study

Variable

Healthcare staff

Information and education

Psychological problem

Physical symptom

Social support

Hospital service

Religious support

Total

Age (years)

  < 40

1.29 ± 1.04a

1.48 ± 1.00

1.21 ± 1.11a

0.91 ± 0.93ab

0.72 ± 0.74

1.32 ± 1.17a

0.65 ± 1.00

1.06 ± 0.84

 40 ~  49

1.53 ± 0.99ab

1.74 ± 0.95

1.39 ± 0.94a

1.13 ± 0.86bc

0.82 ± 0.72

1.62 ± 0.99b

0.96 ± 1.13

1.26 ± 0.76

 50 ~  59

1.69 ± 0.97b

1.78 ± 0.84

1.47 ± 0.96b

1.28 ± 0.85c

0.96 ± 0.79

1.66 ± 1.04b

0.98 ± 1.16

1.37 ± 0.72

  ≥ 60

1.28 ± 0.94a

1.53 ± 0.85

1.06 ± 0.81a

0.80 ± 0.69a

0.70 ± 0.69

1.17 ± 0.97a

0.83 ± 1.13

1.04 ± 0.61

p-value

0.042

0.170

0.096

0.008

0.155

0.030

0.361

0.030

Menopausal status

 Premenopause

1.53 ± 1.00

1.72 ± 0.93

1.35 ± 0.97

1.09 ± 0.86

0.80 ± 0.70

1.57 ± 1.03

0.90 ± 1.13

1.24 ± 0.75

 Postmenopause

1.54 ± 0.98

1.67 ± 0.87

1.37 ± 0.96

1.16 ± 0.87

0.93 ± 0.82

1.50 ± 1.05

0.94 ± 1.12

1.27 ± 0.75

 p-value

0.930

0.648

0.866

0.519

0.144

0.519

0.794

0.652

Time since diagnosis (years)

  ≤ 1

1.56 ± 1.02

1.85 ± 0.85

1.56 ± 0.97

1.28 ± 0.96

0.93 ± 0.83

1.63 ± 1.07

0.99 ± 1.19

1.35 ± 0.79

  > 1, ≤ 3

1.52 ± 0.99

1.71 ± 0.90

1.35 ± 0.96

1.09 ± 0.85

0.86 ± 0.72

1.63 ± 1.00

0.97 ± 1.11

1.27 ± 0.75

  > 3, ≤ 5

1.40 ± 0.95

1.54 ± 0.95

1.18 ± 0.94

0.99 ± 0.79

0.70 ± 0.71

1.39 ± 1.05

0.73 ± 1.07

1.09 ± 0.68

  > 5

1.59 ± 0.97

1.53 ± 0.94

1.26 ± 0.97

1.13 ± 0.82

0.79 ± 0.74

1.22 ± 1.03

0.77 ± 1.07

1.22 ± 0.76

 p-value

0.782

0.172

0.143

0.252

0.324

0.121

0.418

0.235

Family history of breast cancer

 No

1.55 ± 0.98

1.72 ± 0.90

1.37 ± 0.97

1.13 ± 0.86

0.85 ± 0.75

1.59 ± 1.04

0.94 ± 1.13

1.27 ± 0.74

 Yes

1.27 ± 1.05

1.45 ± 0.94

1.24 ± 0.96

1.00 ± 0.93

0.77 ± 0.80

1.01 ± 0.97

0.58 ± 0.99

1.08 ± 0.83

p-value

0.151

0.138

0.486

0.451

0.567

0.006

0.111

0.209

Operation method of breast

 BCS

1.49 ± 0.99

1.67 ± 0.89

1.30 ± 0.96

1.06 ± 0.86

0.81 ± 0.73

1.50 ± 1.03

0.84 ± 1.10

1.24 ± 0.76

 Mastectomy

1.58 ± 0.94

1.77 ± 0.90

1.49 ± 0.96

1.21 ± 0.86

0.92 ± 0.78

1.69 ± 1.03

1.14 ± 1.19

1.41 ± 0.73

  (NA)SSM

1.46 ± 1.05

1.55 ± 1.09

1.38 ± 1.00

1.25 ± 0.84

0.81 ± 0.71

1.43 ± 1.11

0.74 ± 1.01

1.23 ± 0.81

p-value

0.752

0.579

0.344

0.296

0.556

0.325

0.111

0.253

Operation method of axilla

 SLNB

1.48 ± 1.03

1.65 ± 0.93

1.32 ± 0.98

1.08 ± 0.85

0.84 ± 0.78

1.49 ± 1.04

0.94 ± 1.14

1.26 ± 0.78

 ALND

1.57 ± 0.91

1.75 ± 0.85

1.41 ± 0.94

1.19 ± 0.88

0.84 ± 0.68

1.64 ± 1.02

0.85 ± 1.08

1.33 ± 0.72

p-value

0.430

0.308

0.444

0.265

0.954

0.218

0.486

0.453

TNM stage

 0

1.31 ± 0.90

1.36 ± 0.82

1.01 ± 0.97a

0.96 ± 0.91

0.49 ± 0.53a

1.08 ± 0.85a

0.42 ± 0.67

0.93 ± 0.61

 I

1.44 ± 1.02

1.60 ± 0.97

1.21 ± 0.94ab

0.95 ± 0.78

0.69 ± 0.67ab

1.40 ± 1.01ab

0.90 ± 1.13

1.14 ± 0.74

 II

1.60 ± 0.99

1.77 ± 0.83

1.44 ± 0.96ab

1.22 ± 0.88

0.96 ± 0.77b

1.64 ± 1.06b

0.95 ± 1.14

1.32 ± 0.74

 III & IV

1.63 ± 0.94

1.82 ± 0.96

1.62 ± 0.97b

1.31 ± 0.96

1.00 ± 0.85b

1.79 ± 1.04b

1.00 ± 1.15

1.42 ± 0.79

p-value

0.438

0.187

0.030

0.025

0.004

0.036

0.435

0.034

Multiplicity

 No

1.46 ± 0.98

1.66 ± 0.89

1.31 ± 0.95

1.07 ± 0.84

0.81 ± 0.73

1.50 ± 1.04

0.84 ± 1.08

1.20 ± 0.73

 Yes

1.82 ± 0.97

1.86 ± 0.97

1.57 ± 1.01

1.33 ± 0.93

0.99 ± 0.82

1.74 ± 1.03

1.25 ± 1.26

1.48 ± 0.80

p-value

0.011

0.117

0.054

0.035

0.088

0.099

0.011

0.007

Estrogen receptor

 Negative

1.44 ± 0.96

1.63 ± 0.93

1.38 ± 0.99

1.16 ± 0.87

0.92 ± 0.80

1.47 ± 1.10

0.96 ± 1.16

1.25 ± 0.76

 Positive

1.56 ± 1.00

1.72 ± 0.90

1.35 ± 0.96

1.11 ± 0.86

0.83 ± 0.74

1.57 ± 1.02

0.92 ± 1.12

1.25 ± 0.75

p-value

0.360

0.476

0.854

0.697

0.371

0.477

0.804

0.978

Progesterone receptor

 Negative

1.50 ± 0.94

1.71 ± 0.88

1.44 ± 0.95

1.22 ± 0.84

0.92 ± 0.78

1.52 ± 1.04

1.03 ± 1.18

1.31 ± 0.75

 Positive

1.55 ± 1.01

1.70 ± 0.92

1.33 ± 0.97

1.08 ± 0.87

0.83 ± 0.74

1.56 ± 1.04

0.88 ± 1.11

1.23 ± 0.75

p-value

0.696

0.959

0.346

0.199

0.291

0.773

0.277

0.426

HER2

 Negative

1.48 ± 0.99

1.64 ± 0.93

1.29 ± 0.96

1.07 ± 0.86

0.77 ± 0.70

1.46 ± 1.03

0.86 ± 1.14

1.19 ± 0.74

 Positive

1.63 ± 0.98

1.84 ± 0.83

1.52 ± 0.95

1.22 ± 0.86

1.01 ± 0.84

1.73 ± 1.05

1.03 ± 0.10

1.38 ± 0.74

p-value

0.214

0.059

0.505

0.139

0.015

0.035

0.220

0.039

Chemotherapy

 No

1.49 ± 1.03

1.53 ± 0.91

1.26 ± 1.00

0.97 ± 0.81

0.75 ± 0.74

1.43 ± 1.02

1.05 ± 1.15

1.21 ± 0.76

 Yes

1.52 ± 0.97

1.74 ± 0.90

1.39 ± 0.95

1.16 ± 0.88

0.87 ± 0.74

1.58 ± 1.04

0.86 ± 1.10

1.31 ± 0.76

p-value

0.821

0.071

0.298

0.099

0.238

0.283

0.183

0.349

Hormonal therapy

 No

1.53 ± 0.98

1.70 ± 0.92

1.40 ± 0.99

1.21 ± 0.92

0.90 ± 0.80

1.52 ± 1.12

0.85 ± 1.09

1.31 ± 0.78

 Yes

1.50 ± 0.99

1.69 ± 0.90

1.34 ± 0.95

1.07 ± 0.84

0.81 ± 0.72

1.55 ± 1.00

0.93 ± 1.13

1.28 ± 0.75

p-value

0.801

0.938

0.624

0.201

0.320

0.858

0.585

0.753

Radiation therapy

 No

1.45 ± 0.93

1.69 ± 0.89

1.50 ± 0.92

1.16 ± 0.86

0.92 ± 0.78

1.52 ± 1.08

1.02 ± 1.15

1.32 ± 0.75

 Yes

1.52 ± 1.00

1.69 ± 0.91

1.31 ± 0.97

1.10 ± 0.86

0.81 ± 0.73

1.54 ± 1.02

0.87 ± 1.11

1.27 ± 0.76

p-value

0.601

0.999

0.168

0.582

0.322

0.880

0.361

0.630

Target therapy

 No

1.48 ± 0.99

1.66 ± 0.92

1.30 ± 0.97

1.06 ± 0.86

0.78 ± 0.72

1.48 ± 1.03

0.87 ± 1.12

1.24 ± 0.75

 Yes

1.59 ± 0.99

1.81 ± 0.83

1.53 ± 0.91

1.29 ± 0.86

1.03 ± 0.81

1.77 ± 1.04

1.03 ± 1.12

1.44 ± 0.77

p-value

0.462

0.189

0.085

0.056

0.016

0.050

0.312

0.063

Co-morbidity

 No

1.46 ± 0.94

1.78 ± 0.83

1.40 ± 0.94

1.19 ± 0.85

0.86 ± 0.73

1.52 ± 1.00

0.99 ± 1.17

1.28 ± 0.73

 Yes

1.52 ± 1.00

1.66 ± 0.93

1.34 ± 0.97

1.07 ± 0.86

0.82 ± 0.73

1.54 ± 1.04

0.91 ± 1.12

1.22 ± 0.75

p-value

0.679

0.327

0.635

0.332

0.651

0.908

0.626

0.563

Adjuvant treatment

 During

1.50 ± 1.01

1.81 ± 0.88

1.43 ± 0.98ab

1.21 ± 0.91ab

0.94 ± 0.77b

1.60 ± 1.08

0.99 ± 1.16

1.32 ± 0.77a

 After

1.47 ± 0.96

1.58 ± 0.91

1.20 ± 0.91a

0.98 ± 0.76a

0.69 ± 0.67a

1.46 ± 1.00

0.81 ± 1.09

1.13 ± 0.68ab

 Othersa

1.77 ± 0.97

1.75 ± 0.97

1.67 ± 1.01b

1.27 ± 0.98b

1.01 ± 0.81b

1.62 ± 1.04

1.06 ± 1.13

1.43 ± 0.83b

p-value

0.165

0.103

0.009

0.039

0.005

0.471

0.260

0.022

  1. Abbreviations: BCS breast conserving surgery, (NA) (nipple areolar), SSM skin sparing mastectomy, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection
  2. a: Others: palliative treatment for recurrence, complementary treatment or simple follow-up etc